Diabetes, Vol 47, Issue 1 87-92, Copyright © 1998 by American Diabetes Association

ARTICLES

Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia

M Federici, D Lauro, M D'Adamo, B Giovannone, O Porzio, M Mellozzi, G Tamburrano, P Sbraccia and G Sesti
Laboratory of Molecular Medicine, University of Rome, Italy.

The insulin receptor (IR) shares structural and functional homology with the IGF-I receptor (IGF-IR). Hybrid receptors composed of an IR alphabeta-heterodimer and an IGF-IR alphabeta-heterodimer are formed in tissues expressing both molecules. Hybrids behave as IGF-IR rather than IR with respect to ligand binding affinity, receptor autophosphorylation, and hormone internalization and degradation. Factors regulating hybrid formation in vivo are unknown. We recently reported that in skeletal muscle of NIDDM patients, expression of hybrids is increased and correlated with a decrease in IR number and an increase in fasting insulin levels. However, it is not clear whether increased expression of hybrid receptors is a primary defect specifically associated with NIDDM or a secondary event caused by hyperinsulinemia. To address this issue, we used a quantitative microwell-based immunoassay to measure hybrid receptor abundance in skeletal muscle of 11 normal subjects and 12 patients with insulinoma, a state of primary nongenetically determined hyperinsulinemia. Total insulin binding was lower in insulinoma patients than in normal subjects (0.70 +/- 0.18 vs. 4.59 +/- 0.77; P < 0.0001). Total IGF-I binding did not differ between the two groups (0.81 +/- 0.27 and 0.85 +/- 0.10, respectively). The amount of hybrids, expressed as bound/total (B/T), was higher in patients with insulinoma than in normal subjects (0.57 +/- 0.19 vs. 0.36 +/- 0.03; P < 0.0006) and was inversely correlated with total insulin binding (r = -0.64, P < 0.0004). Increased abundance of hybrid receptors was positively correlated with insulin levels (r = -0.82, P < 0.0009) and inversely correlated with insulin-mediated glucose uptake (r = -0.80, P < 0.01). No correlations were observed between insulin-mediated glucose uptake and maximal specific insulin binding (r = 0.19, P = 0.64). These results indicate that insulin-induced IR downregulation may lead to the formation of a higher proportion of hybrid receptors, whose abundance is negatively correlated with in vivo insulin sensitivity. These results, therefore, support a role for insulin in the regulation of hybrid receptors formation and suggest that increased expression of hybrids in NIDDM may be a secondary event caused by hyperinsulinemia rather than a primary defect.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L. J. Murphy Insulin-like growth factor-I: a treatment for type 2 diabetes revisited. Endocrinology, June 1, 2006; 147(6): 2616 - 2618. [Full Text] [PDF]

				G. Sesti, A. Sciacqua, M. Cardellini, M. A. Marini, R. Maio, M. Vatrano, E. Succurro, R. Lauro, M. Federici, and F. Perticone Plasma Concentration of IGF-I Is Independently Associated With Insulin Sensitivity in Subjects With Different Degrees of Glucose Tolerance Diabetes Care, January 1, 2005; 28(1): 120 - 125. [Abstract] [Full Text] [PDF]

				C. D Byrne Programming other hormones that affect insulin: Type 2 diabetes Br. Med. Bull., November 1, 2001; 60(1): 153 - 171. [Abstract] [Full Text] [PDF]

				A. M. Fernandez, J. K. Kim, S. Yakar, J. Dupont, C. Hernandez-Sanchez, A. L. Castle, J. Filmore, G. I. Shulman, and D. Le Roith Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes Genes & Dev., August 1, 2001; 15(15): 1926 - 1934. [Abstract] [Full Text] [PDF]

				D. Spampinato, G. Pandini, A. Iuppa, V. Trischitta, R. Vigneri, and L. Frittitta Insulin/Insulin-Like Growth Factor I Hybrid Receptors Overexpression Is Not an Early Defect in Insulin-Resistant Subjects J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4219 - 4223. [Abstract] [Full Text]

				K. Cusi and R. DeFronzo Recombinant Human Insulin-Like Growth Factor I Treatment for 1 Week Improves Metabolic Control in Type 2 Diabetes by Ameliorating Hepatic and Muscle Insulin Resistance J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3077 - 3084. [Abstract] [Full Text]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				M. García-de Lacoba, C. Alarcón, E. J. de la Rosa, and F. de Pablo Insulin/Insulin-Like Growth Factor-I Hybrid Receptors with High Affinity for Insulin Are Developmentally Regulated during Neurogenesis Endocrinology, January 1, 1999; 140(1): 233 - 243. [Abstract] [Full Text]